Innovative Advances in Coagulation Diagnostics by Perosphere
Perosphere Technologies to Present at International Symposium
Perosphere Technologies Inc., a pioneering medical technologies company, has announced its participation in a significant upcoming event focusing on critical and point-of-care testing. The company is set to present findings at the 29th ADLM International Critical & Point of Care Testing (CPOCT) Symposium. This event highlights innovation in the medical field and provides a platform for discussing advancements in diagnostic technologies.
Presentation Highlights by CEO Dr. Sasha Bakhru
At the symposium, CEO Dr. Sasha Bakhru will deliver an oral presentation that emphasizes the innovative capabilities of the Perosphere ClotChek™ coagulometer. Dr. Bakhru’s presentation will focus on the accuracy of Whole Blood Clotting Time (WBCT) assessments for patients using direct oral anticoagulants (DOACs). This advancement is notably significant as it compares anticoagulated patients with normal, non-medicated individuals.
“We express our gratitude to the ADLM for organizing this event, showcasing the latest developments in critical testing,” stated Dr. Bakhru. His insights and data will underline how Perosphere ClotChek™ fills a vital gap for patients on DOACs who are at risk for bleeding complications.
Overview of Oral Presentation and Posters
Dr. Bakhru, recognized for his contributions to the field, will spotlight results from a pivotal study that reveals the responsiveness of the Perosphere ClotChek to various levels of anticoagulation in whole blood samples. His findings will not only delineate the differences observed at peak and minimal anticoagulation but will also showcase how ClotChek results correlate with those from normal subjects.
Details of the Oral Presentation
Title: Clinical Performance of a Novel Point-of-Care Coagulometer for the DOACs
Presenter: Sasha Bakhru, PhD, CEO, Perosphere
Date: September 26, 2024
Time: 3:15 - 3:30 pm
Scientific Posters Showcasing Innovative Technology
In addition to Dr. Bakhru's oral presentation, Perosphere will showcase two posters among 32 featured at the symposium. These posters will provide insights into the performance of the coagulometer regarding accuracy, linearity, and precision when utilizing venous whole blood samples and quality controls.
Specifics of the Poster Presentation
Title: Accuracy and Precision Evaluation of a Novel Point-of-Care Coagulometer for the DOACs
Author: Dardan Osmani, MS, MBA, Director of Technical Operations, Perosphere
Impacts of Perosphere ClotChek on Patient Care
The data presented at the symposium showcases the Perosphere ClotChek's innovative approach to coagulation diagnostics. This novel device offers rapid WBCT results in a timeframe of 3-8 minutes, using just a single drop of fresh whole blood from a venous sample. This accessibility can vastly improve patient management, particularly for those undergoing anticoagulant treatments.
About Perosphere Technologies
Perosphere Technologies is committed to transforming diagnostic procedures at the point of care in both hospital settings and outpatient clinics. The company focuses on bringing its flagship product, Perosphere ClotChek™, to market. This coagulometer is designed to provide instantaneous and precise diagnostic information that supports clinicians in making informed treatment decisions for patients at risk of bleeding.
With a focus on enhancing the standards of care for patients using anticoagulation therapies, Perosphere ClotChek™ not only aims to elevate efficiency and reduce costs but also aspires to improve patient outcomes significantly.
Contact Information
To learn more about Perosphere Technologies or its offerings, interested parties can reach out via email or phone. For inquiries, please contact the company for further information.
Frequently Asked Questions
What is Perosphere Technologies focused on?
Perosphere Technologies is dedicated to developing advanced coagulation diagnostics to enhance patient care and treatment decisions.
What is the Perosphere ClotChek™?
The Perosphere ClotChek™ is a novel point-of-care coagulometer designed to rapidly and accurately measure whole blood clotting times.
When will Perosphere present its findings?
The company will present its findings at the 29th ADLM CPOCT Symposium, taking place between September 25-27, 2024.
Who will be presenting on behalf of Perosphere?
Dr. Sasha Bakhru, the CEO of Perosphere, will lead the oral presentation highlighting the device's capabilities.
What can attendees expect from the presentations?
Attendees can look forward to insights into the effectiveness and precision of the Perosphere ClotChek in measuring WBCT for patients utilizing DOACs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- GM and Ford Prepare for Earnings Amid Market Uncertainty
- Skye Bioscience Announces Participation in Key Healthcare Conferences
- Rapid Harvesting of U.S. Corn and Soybeans Sparks Challenges
- Inventus Mining Secures Major Investment from McEwen Mining
- Arvinas, Inc. Plans to Share Q3 2024 Results and Updates
- Seer Unveils Innovative Proteomic Solutions at HUPO 2024
- Akero Strives for Breakthroughs in Metabolic Disease Therapies
- Exciting Trading Competition You Can't Miss: CoinW Legend Cup
- Future of PET MRI: Market Insights and Growth Projections
- Northpoint Charter School's Innovative Tutoring Partnership
Recent Articles
- Global Epoxy Paint Market Set to Soar to $63 Billion by 2034
- Altamira Therapeutics Reports Progress in RNA Delivery Strategies
- Adobe Predicts Unprecedented $240 Billion in Holiday Sales
- Exploring the Future of Connectivity with 6G Market Growth
- Exciting Release of Monster Hunter Wilds by Capcom Set for 2025
- Piper Sandler Adjusts Tyson Foods Rating Amid New Risks
- UFC 306 at Sphere: A New Era for Live Entertainment Events
- Structural Health Monitoring Market Growth Insights for Investors
- Macquarie Analyzes Cryptocurrency Miners with Outperform Ratings
- Zeagoo Marks 11 Years of Fashion with Stylish New Collection
- Exploring the Expanding Bio Plasticizers Market and Growth Trends
- Orbia's Innovative Refrigerant Solution for Automotive Markets
- Projected Growth of the Snow Scooter Industry by 2032
- IntraBio Achieves FDA Approval for Innovative NPC Treatment
- OKX Enhances Trading Experience with New POL Futures Listing
- Ferring's Promising Study Results for Lumbar Disc Herniation
- Navigating Coloplast's Financial Landscape for 2024-25
- Genialis Unveils Groundbreaking Biomarker for Cancer Treatment
- SeaStar Medical Accelerates Enrollment in Groundbreaking AKI Trial
- Exploring the Recent Trends in Home Sales and Stale Listings
- RenovoRx Expands Production of RenovoCath to Meet High Demand
- Lineage Cell Therapeutics Showcases OpRegen® Progress at ISSCR
- Analyzing the Remarkable Gains and Sector Performance
- Fujirebio's Innovative Blood Test Aims to Transform Alzheimer's Diagnosis
- Sonnet BioTherapeutics Implements 1-for-8 Reverse Stock Split
- Hillary Frei Joins Handel’s Homemade Ice Cream as CMO
- Jamie Dimon’s Crusade Against Early Career Poaching Practices
- Byrna Technologies Scheduled to Reveal Q3 2024 Outcomes Soon
- Apogee Enterprises Acquires UW Solutions to Enhance Growth
- Innovative Drug Testing Solution for Thanet Earth Workers
- New Financing Initiatives to Enhance Global Health Access
- Alcoa Corporation Sets Date for 2024 Q3 Earnings Call
- Data Storage Corporation Expands Service Contracts with Major Client
- Home Hardware Stores Leads Environmental Charge Through Tree Planting
- Freeport Announces Cash Dividends for Common Stock Holders
- SBC Medical Group's Nasdaq Debut Boosts HeartCore's Growth
- Unveiling Holiday Sales Trends: E-Commerce Takes Center Stage
- Bill Nye's Compassionate Campaign for Ataxia Awareness
- KULR Expands $2.4M Battery Contract with U.S. Army for 2025
- Data Storage Corporation Expands Managed Services for Clients
- Allonnia and Mining3 Join Forces to Innovate Sustainable Mining
- Entera Bio and OPKO Health Unveil Breakthrough Oxyntomodulin Results
- KULR Technology Group Expands Army Battery Contract to $2.4M
- Brenmiller Energy Partners with Leaders to Enhance bGen™ Growth
- Exploring the Future of 6G Technology and Its Rapid Growth
- Neuronetics Expands TMS Access for Adolescents with MDD
- Elevating Fleet Management: Merchants Fleet and Ridecell Unite
- Future of Structural Health Monitoring Market Looks Bright
- PTX Metals Expands Uranium Footprint in Thelon Basin Region
- Enveric Biosciences Pioneers Innovative Non-Hallucinogenic Therapy